SGLT2 INHIBITORS DECREASE CARDIOVASCULAR DEATH AND HEART FAILURE HOSPITALIZATIONS: A SYSTEMATIC REVIEW
Keywords:
Cardiovascular disease, Heart failure, Sodium-glucose cotransporter 2 (SGLT2) inhibitorsAbstract
According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death from noncommunicable diseases (NCDs). It is responsible for 17.5 million deaths, which accounts for 46% of all deaths caused by noncommunicable diseases. Additionally, 80% of these deaths occur in low-middle income countries, and it is anticipated that this number will rise to 23.6 million in 2030. SGLT2 inhibitors are currently indicated as first- or secondline therapies of type 2 diabetes mellitus (T2DM) in patients who have established cardiovascular disease, high or very high cardiovascular risk, renal illness, or heart failure. This is the case in both Europe and the United States of America. In individuals who already have heart failure, taking SGLT2 inhibitors lowers the overall mortality risk as well as the chance of death from cardiovascular causes. Patients who are at a higher risk of dying as a whole are the ones who have proved to benefit from this. It has been established that SGLT2 inhibitors reduce the risk of cardiovascular mortality as well as the rate of hospitalizations and urgent care visits that are associated with heart failure in a range of different populations.
References
Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. Juli 2015;314(1):52–60.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. Januari 2009;360(2):129–39.
Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. Juni 2015;372(23):2197–206.
Zipes D, Libby P, Bonow R. Braunwald’s Heart Disease. 8 ed. Philadelphia: Elsevier; 2019.
Ponikowski P; Voors AA; Anker SD; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129–200.
Cagle SD, Cooperstein N. Coronary Artery Disease: Diagnosis and Management. Prim Care. 2018;45(1):45–61.
Yadav YK. Exercise in the Management of Coronary Artery Disease. Med journal, Armed Forces India. Oktober 2007;63(4):357–61.
Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
Verma S, McMurray JJ V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. Oktober 2018;61(10):2108–17.
Cardoso R, Graffunder FP, Ternes CMP, Fernandes A, Rocha A V, Fernandes G, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and metaanalysis. EClinicalMedicine. Juni 2021;36:100933.
Liu B, Wang Y, Zhang Y, Yan B. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Curr Top Med Chem. 2019;19(20):1818–49.
Lu H, Meyer P, Hullin R. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how? Swiss Med Wkly. Agustus 2020;150:w20341.
de Boer RA, Núñez J, Kozlovski P, Wang Y, Proot P, Keefe D. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. Juli 2020;86(7):1346–56.
Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. Juli 2018;138(5):458–68.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. Agustus 2017;377(7):644–57.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. Maret 2021;77(11):1381–92.
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. Januari 2018;137(2):119–29.
McMurray JJ V, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. November 2019;381(21):1995–2008.
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. April 2020;323(14):1353–68.
Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang C-E, Diez M, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. Oktober 2021;23(10):1662– 72.
Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. Maret 2020;29(2):190–8.
Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. Maret 2018;25(5):495–502.
Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, et al. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. Stroke. Mei 2021;52(5):1545–56.
Zheng R-J, Wang Y, Tang J-N, Duan J-Y, Yuan M-Y, Zhang J-Y. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol [Internet] 2022;79(2). Tersedia pada: https://journals.lww.com/cardiovascularpharm/Fulltext/2022/02000/Association_of_SGLT2_Inhibitors_With_Ris k_of.1.aspx
International Diabetes Federation. Diabetes. Brussels: IDF; 2017.
Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs [Internet] 2019;79(10):1135–46. Tersedia pada: https://doi.org/10.1007/s40265-019-01148-3
Peng X, Li L, Zhang M, Zhao Q, Wu K, Bai R, et al. Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction. Front Physiol. 2020;11:912.
Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Hear. September 2021;8(2).
Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. Februari 2015;3(2):136–45.
Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. Januari 2018;71(3):339–51.
McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. Februari 2019;73(5):602–11.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
